Featured News

Oxynade by SecuTix offers free to use platform until April 2021

Belgium-based provider of e-Ticketing-as-a-service (eTaaS) Oxynade by SecuTix has announced its platform will be free to use for new clients until April 2021.

The move is part of the company’s response to the COVID-19 crisis, which has seen the live events and ticketing sectors decimated due to cancellations and postponements.

Oxynade by SecuTix is opening the free use offer to both established ticketing companies and professionals who want to start their own ticketing business, without the costs and the risks a start-up usually entails.

The firm has indicated that there are a limited number of places and interested parties should apply online before the end of June.

Those who are selected must agree to a multi-year contract with Oxynade by SecuTix and in return, there will be no monthly licensing costs and no other ticket fees charged until after April 2021.

Hans Nissens (pictured above), managing director of Oxynade by SecuTix, said: “Paying nothing until next year will allow clients to benefit right now from cutting-edge ticketing technology adapted to meet today’s challenges.

“In just the last few weeks alone, we’ve introduced a time slot entry feature and added chessboard seating management. But ticketing will be heavily impacted for a long time, and we will work with new clients to build a more sustainable future for their ticketing business.”

The firm also promised that current Oxynade clients will also be assisted with a “customised support package”.

Oxynade’s eTicketing-as-a-Service solution (eTaaS) is a unified self-service platform, fully API based, highly customisable and 100 per cent white-label. The platform was developed to focus on freeing smaller and medium-sized ticketing businesses from typical constraints and on providing an alternative to in-house development and industry monoliths.

SecuTix, a European developer of an integrated, cloud-based platform for white-label ticketing and audience management, acquired Oxynade in January 2020.